New Job Opportunity

Pharmascience Expands its CDMO Services With a New Commercial Business Unit

Pharmascience, the largest Canadian-owned pharmaceutical company, announced a major $120 million sterile injectable manufacturing facility expansion at its Candiac site. Following this important milestone, the company is now proud to announce the expansion of its contract development and manufacturing organization (CDMO) services with the creation of a new business unit dedicated to injectable products. This new business unit will help accelerate production and achieve Pharmascience's growth objectives by enabling the company to offer its R&D, formulation and manufacturing services to external pharmaceutical partners. It will focus more specifically on injectable products, with a mandate to offer CDMO services to biotech companies and those with complex injectable product development or manufacturing needs. Pharmascience's ambition is to become a world leader in the sterile injectable CDMO segment and serve pharmaceutical companies with world class services to meet the needs of customers and patients worldwide. "With a vision to continue our expansion while supporting local development and manufacturing, we see a tremendous opportunity to expand our services to meet the needs of a growing pharmaceutical client base, whose complex injectable product supply requirements can be met by the extraordinary expertise of the Pharmascience team. Creating our new CDMO business unit represents an excellent way to maximize the value of our research and development efforts and the value of every unit we produce at our Candiac plant," says Martin Arès, CEO of Pharmascience. Appointment of John Foy as General Manager, CDMO Alongside the creation of this new CDMO business unit, Pharmascience is pleased to welcome John Foy as General Manager, CDMO since February. Mr. Foy is a seasoned leader with an MBA from the University of North Carolina and a mechanical engineering degree from Lehigh University in Pennsylvania and has spent the last 24 years working at CDMOs, specializing in complex biologics and pharmaceuticals. He also has in-depth knowledge of the U.S. market knowledge, strategic thinking and market development expertise. His extensive experience and proven leadership will undoubtedly be major assets in helping Pharmascience position its CDMO business unit as a world leader in the sterile injectable products segment. Pharmascience is pleased with its team's progress on the Candiac expansion project since the announcement last October. By 2026, the company will invest over $120 million to expand its facilities and more than triple its capacity with new state-of-the-art equipment. This will enable the company to support more patients, with annual production rising to more than 20 million units. This expansion is already well underway and will also enable Pharmascience to compete with international players and broaden its client base with a new range of products and services.

Synthetic biology to create 50k new jobs by 2040

Synthetic biology could underpin an industry worth up to $30 billion per year and create over 50,000 new jobs by 2040, according to a new report by Australia’s national science agency, Commonwealth Scientific and Industrial Research Organisation (CSIRO), and Main Sequence Ventures. The Synthetic Biology National Progress Report is an update to the 2021 National Synthetic Biology Roadmap which originally found the field would deliver an annual revenue of $27 billion and 44,000 jobs by 2040. New projections have seen this figure increase to $30 billion and 50,000 new jobs, and the report found Australian synthetic biology startups received over $363 million in capital investments over the past three years. According to CSIRO’s Health and Biosecurity Futures lead, Greg Williams, Australia has continued to foster a strong synthetic biology research and development ecosystem, with $44.5 million in research grants distributed over the last three years. Gabrielle Munzer, Partner at Main Sequence Ventures, said that venture capital investment into cutting edge synthetic biology applications promises to deliver transformative benefits across a range of sectors.

Daiichi Sankyo's Pfaffenhofen Site to Transform into Global Innovation Center, Adding 350 New Jobs

With investments of approximately one billion euros, Japan headquartered Daiichi Sankyo will expand its production and development site in Pfaffenhofen an der Ilm, north of Munich, into an international innovation centre. At least 350 new jobs will be created by 2030, including numerous positions for top international researchers, process engineers and other specialists in sterile and biotechnology. In addition to more production capacities in the area of cardiovascular diseases, new laboratories will be created, particularly for antibody drug conjugate (ADC) technology. In the future, novel cancer therapies against, among other things, breast, lung and stomach cancer will be developed and manufactured in Pfaffenhofen. The Pfaffenhofen production site has stood for the highest quality standards for more than 60 years. The medicines produced at the factory are shipped to more than 50 countries worldwide. Pharmaceutical development is also already taking place at the site. In addition, Pfaffenhofen is one of Daiichi Sankyo's largest sites in the world for the production of clinical products. One of the elements of the investment is the new building for Daiichi Sankyo's ADC, which is scheduled to be completed by the end of 2026. In addition to the areas of production and research, the investments also strengthen quality assurance and logistics. Renewable energies will play an increasingly important role: the plant already relies on wind, water, biomass and solar energy, which it generates itself either with its own systems or in cooperation with local partners.

Amgen Opens Cutting-Edge Manufacturing Site in Central Ohio, adding 400+ jobs

Amgen announced the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the most advanced facility to date. "Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient, every time,'" said Robert A. Bradway, chairman and chief executive officer at Amgen. "As part of Amgen's global biomanufacturing network, Amgen Ohio will play an important role in helping us address serious disease around the world with our innovative biomedicines." The nearly 300,000-square-foot facility will employ 400 full-time staff. It also features open workspaces to foster collaboration and has been designed to meet the highest environmental sustainability standards, in support of Amgen's commitment to achieve carbon neutrality for all operations by 2027. "This new Ohio facility is a success story in advanced healthcare manufacturing and the Made-in-America supply chain we need to live and thrive," said Lt. Governor Jon Husted. "Winning this project for Ohio creates 400 high-paying jobs and a $40 million annual payroll, supporting families and further growing the Ohio economy." Amgen is a strong supporter of the communities in which its staff members work and live. In partnership with Columbus State Community College, Amgen is hosting an inaugural 18-month manufacturing apprenticeship at the site. This program, designed for those new to the field or changing careers, offers a blend of classroom and practical training, aiming to expand opportunities for skilled individuals without the requirement for a formal bachelor's degree.

Singapore's MoH Introduces Long-Term Retention Scheme for Nursing Career

To attract and encourage nurses to build a lifelong career in nursing, the Ministry of Health (MoH) in Singapore will introduce a long-term retention scheme for nurses working in the public healthcare system in September 2024. Under the Award for Nurses' Grace, Excellence and Loyalty (ANGEL) scheme, all new and in-service nurses working in the public healthcare institutions (PHIs) can receive a total payout of up to $100,000 over the next 20 years of their career. In total, about 29,000 nurses stand to benefit from the ANGEL scheme. Minister for Health Ong Ye Kung announced this at an event at the National University Hospital recently. Newly recruited nurses and nurses aged below 46 years old will receive payouts every four to six years, from the time they onboard onto the scheme, with each payout ranging from $20,000 to $30,000 (see the Annex for illustration of ANGEL payout schedule). The majority of nurses serving in public healthcare join the profession at a young age, and will be able to enjoy the full benefits of ANGEL if they stay on to pursue a career in nursing. Foreign nurses who have been in continuous service for at least four years and demonstrate their commitment to Singapore’s public healthcare system will also be eligible. To recognise the contributions of long-serving in-service nurses aged 46 years and above who do not have sufficient career runway to reach the four milestones before retirement age, and encourage them to serve even longer, they will receive a one-off recognition payout of $5,000 to $15,000, depending on their years of service and if they have at least five years in-service. Subsequently, their payouts will be on an accelerated schedule, where they will receive payouts every third year. The maximum payout per nurse is up to $100,000 or when they reach the prevailing retirement age, whichever is sooner. Eligible nurses on post-retirement contracts will also receive the one-off recognition payout if they have at least five years in-service.

National Resilience to Expands it's Drug Manufacturing Capacity with $225M Investment

National Resilience, Inc. announced the expansion of the company’s clinical and commercial drug product manufacturing capabilities across its network. By scaling this capacity, Resilience aims to provide over 200 million units to its partners across its manufacturing network by 2025 in support of multiple modalities and therapeutic indications, including GLP-1. Resilience’s pre-clinical, clinical and commercial cGMP manufacturing network was built to help withstand unforeseen difficulties like capacity constraints, raw material supply chain shortages and disruptions. This expansion addresses the biomanufacturing industry’s growing demands within the drug product space, further responding to industry needs. In Cincinnati, at least $225 million is planned to be invested to increase the site’s drug product capacity. The FDA-licensed site currently has three high speed fill lines for Vials, Cartridges and pre-filled syringes (PFS), with a fourth PFS fill line ready by 2025. The facility is also expanding to six device assembly and packaging suites by 2025 to meet the industry’s growing biomanufacturing demands. The licensed site has a longstanding history of supplying commercial medicines worldwide. Additionally, Resilience is expanding its drug product capabilities at the company’s RTP facility in North Carolina using a modular design within its segregated expansion space to offer drug product manufacturing for multiple modalities. The site has drug substance and drug product experience in support of Gene Therapy medicines. It also has 45,000 square feet of grey space available for additional expansion that will be leveraged for drug product operations. As part of the growth plans, a new state-of-the-art Bausch & Strobel Isolator filler will be installed to support Vials and PFS, providing flexibility and quality assurance with its barrier isolation technology. “Strengthening our drug product manufacturing capacity across the Resilience network highlights our commitment to providing robust and scalable outsourcing options for our partners,” said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience. “As a highly experienced team already supporting a leading pharmaceutical company with their GLP-1 products, this expansion further supports Resilience’s mission to ensure adequate biomanufacturing capacity by addressing and overcoming historic manufacturing challenges throughout the industry.”

Enable Injections Expanding Operations, Adding 450+ Jobs

 Enable Injections, Inc., a leading innovator in developing and manufacturing the enFuse® platform of wearable technology, announced it plans to expand manufacturing operations with a new large-scale facility in Springdale, Ohio as well as enhance the Company's corporate headquarters in Evendale, Ohio. The Company's new 90,000 square-foot Manufacturing Center of Excellence will support ongoing in-house manufacturing and supply of the Company's enFuse medicine delivery technology. enFuse is the first-ever hands-free wearable technology that allows patients to self-administer large-volume medications subcutaneously without an IV or syringe pump. "Scalable, in-house manufacturing is a key pillar of Enable's strategy to accelerate supply of our innovative enFuse technology as the Company continues to grow our roster and scope of clinical and commercial engagements with pharmaceutical partners. This new facility allows Enable to significantly expand and enhance production processes and ultimately reduce the time it takes to bring our enFuse system to patients and the medical community," said Mike Hooven, Chairman and CEO of Enable Injections. "We are proud to have grown our business in Ohio over the last decade and are thankful for the continued support from the state and local organizations as we expand our business operations and footprint." The commitment to increase the Company's manufacturing facilities and capabilities follows U.S. FDA approval and launch of the Company's first enFuse combination product. Enable expects to begin occupying its new Manufacturing Center of Excellence by the end of 2024. As the facility becomes operational, the new location and Evendale headquarters will retain and add more than 450 jobs over the next ten years to the Cincinnati area. The State of Ohio, JobsOhio, the City of Evendale, the City of Springdale, and REDI Cincinnati provided support for Enable's expansion. "We and our partners at REDI Cincinnati welcome Enable Injections' decision to grow operations in the U.S. and bring new career opportunities and investment to Ohio," said JobsOhio President and CEO J.P. Nauseef. "Enable is a global leader in drug delivery, improving the lives of patients worldwide, and we look forward to a continued partnership." In addition to the new Manufacturing Center of Excellence in Springdale, Enable will be renovating and enhancing the infrastructure of its Evendale headquarters. The Company's headquarters presently houses GMP-compliant manufacturing space to support current clinical and commercial demand of enFuse, as well as labs and administrative areas.

Syra Health Secures Nursing Contract with Fairfax County

Syra Health, a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced a healthcare workforce contract with the County of Fairfax, Virginia where the Company will staff licensed nurses to provide 24-hour nursing care. The Company will also staff other temporary healthcare positions. This is Syra Health's third active government contract in the state of Virginia. All three contracts provide healthcare staffing, fulfilled by Syra Health's Healthcare Workforce business unit. Under this contract, Syra Health will deploy its expertise in healthcare staffing to assist the County of Fairfax in meeting its clinical workforce requirements. This collaboration aligns with Syra Health's commitment to advancing healthcare beginning with the personnel that makes healthcare possible. Sandeep Allam, Executive Chairman and President of Syra Health said, "Our dedication to enhancing healthcare extends beyond traditional models. By providing top-tier clinical staffing, we aim to contribute to the County of Fairfax's commitment to delivering quality healthcare services to its community."

AstraZeneca creates employment opportunity at its new manufacturing site in Rockville

AstraZeneca is investing $300 million in a state-of-the-art facility in Rockville, MD to launch its life-saving cell therapy platforms in the US for critical cancer trials and future commercial supply. More than 150 new highly skilled jobs will be created to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world. Over time, the site may expand its focus to support other disease areas. The site represents the latest investment in cell therapy for AstraZeneca following collaborations with Quell therapeutics, AbelZeta, Cellectis, and the acquisition of Neogene Therapeutics. The facility in Rockville, MD is located less than five miles away from one of the company’s five global R&D centres and sits within the booming life sciences corridor in Maryland. With close proximity to several universities, the life sciences ecosystem provides an attractive environment for recruiting new and experienced talent. The new facility will join AstraZeneca’s global manufacturing and supply network of nearly 30 manufacturing and supply sites in 16 countries, which are either currently operational or under development across the company. In the US, AstraZeneca’s manufacturing sites focus on the production of small molecules and biologics, harnessing leading pharmaceutical technology and development. Together, the US manufacturing sites employ more than 2,600 full-time employees and deliver more than 9 billion doses of medicines annually.

Globalmed logistix announces opening of new facility to create medical device and healthcare logistics campus in atlanta

GlobalMed Logistix (GMLx), a leading provider of Value Added Services and Third-Party Logistics (3PL) Services for the medical device industry, is announcing the 65,000 square foot expansion of its Atlanta-based campus located at 1880 and 1890 Beaver Ridge Circle in Norcross, GA. This new facility solidifies the completion of the 125,000 square foot GMLx Atlanta Campus. GMLx was founded to create win-win partnerships with both emerging growth and leading medical device manufacturers from all over the world, acting as their full turn-key outsourced logistics provider in the United States. The expansion reflects the continual increase in demand from healthcare companies for the 45 years of medical device experience and 3PL services that GMLx offers. The updated 65,000 square foot facility will support the company's growth strategy, allowing for the addition of new medical device manufacturer customers as well as an increase in service capabilities for their existing partners. GMLx continues to position itself as a valued partner in the healthcare logistics space, supporting more than 150,000 surgical cases and orders per year at over 3,000 healthcare facilities across the county and to over 25 countries throughout the world. "At GMLx, we believe in our mantra of 'together we grow,'" said Scott Vane, President and Chief Operating Officer, "and this expansion is a testament to the power of that collaboration. Over the past year, we've welcomed a remarkable number of team members and supported a record number of customers and transactions. The collective strides we've made have not only strengthened our organization but have positively impacted the customers and patients we serve. As we look to the future, we're excited about this opportunity to continue that growth." While the main warehouse is managed at ambient conditions, this best-in-class medical device grade facility includes a dedicated environmental control room to meet the demands of devices with stringent temperature and humidity requirements. Additionally, a segregated, 5,700 square foot area is dedicated to Quality Control Services which include AQL inspections, functional testing, and supplier coordination for sterilization. This upgraded facility also allows for the support of customers' cold chain logistics needs. As GMLx continues to expand, the company plans to strategically position itself to respond to the medical device industry's growing demand for outsourced value-added services. In 2023, the company added new quality control services, tissue distribution services, and cold chain logistics services to support existing and future customers. In 2024, GMLx will continue to add innovative, specialty services to support industry demand. Hunter Fleetwood, GMLx VP of Sales, added "We are proud of our role in the medical device supply chain and that we get the opportunity to help our customers support patients every single day. This expansion allows GMLx to continue our focus of providing the best services and service levels in the industry so that our customers can continue to deliver life-changing products to facilities all over the world. Our vision is to positively impact the lives of over one million patients every year and this additional facility is a key factor in helping us achieve that goal."